Designing and testing ionizable fats to improve RNA delivery

In 2018, LNPs enabled the first FDA approval of a siRNA drug (Onpattro).

• LNPs have facilitated the development of successful RNA-based therapies, including two SARS-CoV-2 vaccines.
• Each FDA-approved LNP formulation employs a unique ionizable lipid, suggesting its importance in mRNA delivery efficiency.
• The review discusses advances in the chemical structures and synthetic methods of ionizable lipids used for RNA delivery.
• Structure-activity relationships of ionizable lipids are explored, indicating their role in enhancing delivery performance.

Simplified